Gilead Sciences Inc. (GILD)
Gilead initiated with a Buy at Citi
Citi initiated coverage of Gilead with a Buy rating and $125 price target. The firm says that despite the stock's near-term outperformance, it remains bullish based primarily on upside from Biktarvy led near-term HIV growth and lenacapavir driven long-term growth. It sees "upside growth" in Gilead's combined HIV franchise and believes lenacapavir "could boost" its next phase of growth.
GILD or VRTX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Gilead Sciences: Finally Some Real Momentum
Shares of Gilead Sciences, Inc. experienced a downturn early in 2024 due to pipeline setbacks and underwhelming guidance, but shares have seen a significant recovery recently. The company's reliance on its HIV franchise remains high, with recent positive pipeline news and better-than-expected performance driving shares up 50% since summer. Despite reasonable valuations at 13 times adjusted earnings, I'm cautious due to slower oncology growth and the momentum already displayed by the stock.
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook
GILD's Q3 earnings and sales beat estimates on higher HIV, Veklury, oncology and liver disease drug sales. The stock is trading up.
Gilead's Stock Surge: What's Fueling the Momentum?
Gilead Sciences NASDAQ: GILD recently broke its 52-week high and is up over 40% over the past six months. As a leading biopharmaceutical company dedicated to pioneering innovative therapies, Gilead boasts a legacy of groundbreaking discoveries and a solid history of success.
Gilead Sciences Tops Estimates in Q3
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.
Why Gilead's Solid Q3 Earnings Could Point To A Dividend Surprise Next Year
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio and increased demand for COVID-19 therapy Veklury. Oncology remains a weak area, with CAR-T cell therapies underperforming. However, Trodelvy achieved good growth and now accounts for 5% of consolidated product sales. Sales guidance was raised by 2.4%, primarily due to Veklury, while non-GAAP EPS guidance was raised by 16% for several reasons which I will highlight in the article.
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $2.02 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $2.29 per share a year ago.
Gilead's third-quarter earnings beat by a wide margin, and biotech raises guidance
Gilead Sciences Inc.'s stock rose 2% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and COVID-19 treatments.
Gilead 3rd-quarter results beat Wall Street estimates, raises outlook
Gilead Sciences reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%, leading the drugmaker to raise its outlook for full-year earnings.
